ATE474593T1 - Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway - Google Patents

Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway

Info

Publication number
ATE474593T1
ATE474593T1 AT04722319T AT04722319T ATE474593T1 AT E474593 T1 ATE474593 T1 AT E474593T1 AT 04722319 T AT04722319 T AT 04722319T AT 04722319 T AT04722319 T AT 04722319T AT E474593 T1 ATE474593 T1 AT E474593T1
Authority
AT
Austria
Prior art keywords
modulator
treatment
signaling pathway
allergic diseases
notch signaling
Prior art date
Application number
AT04722319T
Other languages
English (en)
Inventor
Mark William Bodmer
Emmanuel Cyrille Pascal Briend
Brian Robert Champion
Andrew Christopher Lennard
Grahame James Mckenzie
Silvia Ragno
Tamara Tugal
George Albert Ward
Lesley Lynn Young
Original Assignee
Celldex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0306582A external-priority patent/GB0306582D0/en
Priority claimed from GB0306583A external-priority patent/GB0306583D0/en
Priority claimed from GB0306644A external-priority patent/GB0306644D0/en
Priority claimed from GB0306640A external-priority patent/GB0306640D0/en
Priority claimed from GB0306654A external-priority patent/GB0306654D0/en
Priority claimed from GB0306626A external-priority patent/GB0306626D0/en
Priority claimed from GB0306650A external-priority patent/GB0306650D0/en
Priority claimed from GB0306621A external-priority patent/GB0306621D0/en
Priority claimed from GB0306622A external-priority patent/GB0306622D0/en
Priority claimed from GB0306651A external-priority patent/GB0306651D0/en
Priority claimed from GB0306624A external-priority patent/GB0306624D0/en
Priority claimed from PCT/GB2003/001525 external-priority patent/WO2003087159A2/en
Priority claimed from GB0312062A external-priority patent/GB0312062D0/en
Priority claimed from PCT/GB2003/003285 external-priority patent/WO2004013179A1/en
Priority claimed from GB0323130A external-priority patent/GB0323130D0/en
Priority claimed from PCT/GB2004/000046 external-priority patent/WO2004060262A2/en
Priority claimed from PCT/GB2004/000263 external-priority patent/WO2004064863A1/en
Application filed by Celldex Therapeutics Ltd filed Critical Celldex Therapeutics Ltd
Publication of ATE474593T1 publication Critical patent/ATE474593T1/de
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04722319T 2003-03-21 2004-03-22 Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway ATE474593T1 (de)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
GB0306582A GB0306582D0 (en) 2003-03-21 2003-03-21 Medical treatment
GB0306583A GB0306583D0 (en) 2003-03-21 2003-03-21 Medical treatment
GB0306626A GB0306626D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306650A GB0306650D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306621A GB0306621D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306622A GB0306622D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306651A GB0306651D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306644A GB0306644D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306640A GB0306640D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306624A GB0306624D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306654A GB0306654D0 (en) 2003-03-22 2003-03-22 Medical treatment
PCT/GB2003/001525 WO2003087159A2 (en) 2002-04-05 2003-04-04 Modulators of the notch signalling pathway and uses thereof in medical treatment
GB0312062A GB0312062D0 (en) 2003-05-24 2003-05-24 Medical treatment
PCT/GB2003/003285 WO2004013179A1 (en) 2002-08-03 2003-08-01 Conjugate of notch signalling pathway modulators and their use in medical treatment
GB0323130A GB0323130D0 (en) 2003-10-03 2003-10-03 Medical treatment
PCT/GB2004/000046 WO2004060262A2 (en) 2003-01-07 2004-01-07 Modulators of notch signalling for use in immunotherpapy
PCT/GB2004/000263 WO2004064863A1 (en) 2003-01-23 2004-01-23 Treatment of autoimmune diseases using an activator for the notch signaling pathway
PCT/GB2004/001252 WO2004082710A1 (en) 2003-03-21 2004-03-22 Treatment of allergic diseases using a modulator of the notch signaling pathway

Publications (1)

Publication Number Publication Date
ATE474593T1 true ATE474593T1 (de) 2010-08-15

Family

ID=36091380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04722319T ATE474593T1 (de) 2003-03-21 2004-03-22 Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway

Country Status (4)

Country Link
US (2) US20060205823A1 (de)
EP (1) EP1646400B1 (de)
AT (1) ATE474593T1 (de)
WO (1) WO2004082710A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2315602A4 (de) 2008-06-26 2011-11-02 Acceleron Pharma Inc Verfahren zur dosierung eines actriib-antagonisten und überwachung von behandelten patienten
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
BR112013009068A2 (pt) 2010-10-15 2016-07-19 Alk Abelló As supressão de uma resposta imune de hipersensibilidade com antígeno não relacionado derivado de material fonte de alérgeno
US20120100163A1 (en) 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
WO2013147793A1 (en) * 2012-03-29 2013-10-03 Fleming Robert J Methods and compositions for modulating notch activity
JP2015514126A (ja) 2012-04-16 2015-05-18 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ 非特異的アレルギー免疫療法において使用するための植物プロフィリンポリペプチド
EP2846818A1 (de) * 2012-05-10 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunmodulatorische verfahren unter verwendung von notch-agonisten
EP2970468B1 (de) 2013-03-13 2021-07-07 Novartis AG Notch2-bindungsmoleküle zur behandlung von atemwegserkrankungen
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
JP6568110B2 (ja) 2014-06-04 2019-08-28 アクセルロン ファーマ， インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
CA2980757A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
KR102534027B1 (ko) * 2016-06-02 2023-05-18 호유 가부시키가이샤 알 알레르기의 항원

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB218068A (en) 1923-05-11 1924-07-03 Thomas Landye Mechanism for shifting belts from fast to loose pulleys and vice versa
US6887475B1 (en) * 1996-11-07 2005-05-03 Lorantis Limited Notch
EP1616958A3 (de) * 1996-11-07 2006-02-08 Lorantis Limited Notch-Liganden zur Verwendung in der Immuntherapie
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
EP1410018A1 (de) 2001-07-25 2004-04-21 Lorantis Limited Methode zur detektion von modulatoren von notch signaltransduktion
EP1525221A1 (de) 2002-08-03 2005-04-27 Lorantis Limited Onjugate von modulatoren des notch-signaltransduktionsweges und deren verwendungin medizinischer behandlung

Also Published As

Publication number Publication date
EP1646400B1 (de) 2010-07-21
EP1646400A1 (de) 2006-04-19
WO2004082710A1 (en) 2004-09-30
US20100303867A1 (en) 2010-12-02
US20060205823A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0414541B8 (pt) compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
DE602004006536D1 (de) Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten
DK1263729T3 (da) Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
ATE476428T1 (de) Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
DE60042035D1 (de) Verfahren und zusammensetzungen zur herstellung von ophtalmischen linsen
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE60305068D1 (de) Behandlung von mastalgie mit4-hydroxy-tamoxifen
RU2004115107A (ru) Способы профилактики и лечения инфекции, вызываемой флавивирусами у животных
DE602004010691D1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
ATE427141T1 (de) Vorrichtung zum bedecken von den augen
ATE345121T1 (de) Verwendung von konjugierter linolsäure zur behandlung der erkältung
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
DE60020833D1 (de) Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties